Bone Biologics received confirmation that the shelf life of its rhNELL-1 differentiated bone growth factor product has been extended to 24 months, delivering on previously-communicated forecasts.
The extended shelf life is validated by ongoing stability data and represents a logical progression from prior validated 12- and 18-month shelf-life milestones. Achieving a 24-month shelf life is expected to enhance manufacturing efficiency, inventory management, supply-chain flexibility, and clinical and commercial readiness as the company advances rhNELL-1 through development.
“This milestone reflects continued execution against our development and manufacturing objectives,” stated Jeff Frelick, Bone Biologics Chief Executive Officer. “We believe extending the expected shelf life of rhNELL-1 to 24 months, as previously forecasted, is an important step toward commercialization, improving manufacturing efficiency, supply-chain flexibility, and product readiness. As we advance rhNELL-1 through clinical development, these operational milestones are expected to support disciplined capital deployment and long-term shareholder value creation.”
Bone Biologics continues to develop rhNELL-1 as a differentiated bone growth factor designed to promote controlled, targeted bone regeneration, particularly in hard-to-heal fusion settings.
Bone Biologics received confirmation that the shelf life of its rhNELL-1 differentiated bone growth factor product has been extended to 24 months, delivering on previously-communicated forecasts.
The extended shelf life is validated by ongoing stability data and represents a logical progression from prior validated 12- and 18-month shelf-life...
Bone Biologics received confirmation that the shelf life of its rhNELL-1 differentiated bone growth factor product has been extended to 24 months, delivering on previously-communicated forecasts.
The extended shelf life is validated by ongoing stability data and represents a logical progression from prior validated 12- and 18-month shelf-life milestones. Achieving a 24-month shelf life is expected to enhance manufacturing efficiency, inventory management, supply-chain flexibility, and clinical and commercial readiness as the company advances rhNELL-1 through development.
“This milestone reflects continued execution against our development and manufacturing objectives,” stated Jeff Frelick, Bone Biologics Chief Executive Officer. “We believe extending the expected shelf life of rhNELL-1 to 24 months, as previously forecasted, is an important step toward commercialization, improving manufacturing efficiency, supply-chain flexibility, and product readiness. As we advance rhNELL-1 through clinical development, these operational milestones are expected to support disciplined capital deployment and long-term shareholder value creation.”
Bone Biologics continues to develop rhNELL-1 as a differentiated bone growth factor designed to promote controlled, targeted bone regeneration, particularly in hard-to-heal fusion settings.
Copy to clipboard 
